Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29

Climb Bio, Inc.

R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.
Cash, equivalents, and marketable securities $146.3M as of March 31; expects to fund ops into 2028 excluding $110M placement.
Budoprutug SC formulation showed robust B-cell depletion similar to IV; Phase 2 pMN trial granted FDA Fast Track Designation.
Initial budoprutug ITP data (low-dose B-cell and platelet) expected June 2026; pMN data Q4 2026.
CLYM116 nonhuman primate-to-human PK/PD modeling and initial safety data to be presented at ERA June 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Climb Bio, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.